Literature DB >> 24463978

Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821.

Ashham Mansur1, José Hinz, Bronja Hillebrecht, Ingo Bergmann, Aron Frederik Popov, Michael Ghadimi, Martin Bauer, Tim Beissbarth, Sabine Mihm.   

Abstract

BACKGROUND: Sepsis is a life-threatening condition. Programmed cell death 1 protein (PD-1), a negative costimulatory molecule, is suggested to be involved in pathogenesis as mortality is associated with high expression and as neutralizing antibodies improve survival in a mouse model. The PD-1 gene harbors an intronic single-nucleotide polymorphism, rs11568821, which is located in a transcription factor-binding site and supposed to affect PD-1 transcription.
OBJECTIVE: This study aimed at investigating whether mortality (90-day) among patients with sepsis associates with PD-1 rs11568821 genotypes.
METHODS: Adult white patients with sepsis from the surgical intensive care units of a university medical center were followed up for 90 days, and mortality was recorded as primary outcome variable. Blood samples were taken for PD-1 rs11568821 genotyping. Sequential Organ Failure Assessment scores increased at enrollment and during the observation period to monitor morbidity.
RESULTS: Two hundred nineteen critically ill patients with sepsis were enrolled in this investigation. Ninety-day mortality was significantly higher among G homozygotes than among A allele carriers (P = 0.0032). During intensive care unit stay, G homozygotes experienced higher Sequential Organ Failure Assessment scores (P < 0.001) and a higher demand of vasopressor therapy (P = 0.0107).
CONCLUSIONS: Data provide first associative evidence for PD-1 rs11568821 as a prognostic indicator in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24463978     DOI: 10.2310/JIM.0000000000000059

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  11 in total

1.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

2.  The CD14 rs2569190 TT Genotype Is Associated with an Improved 30-Day Survival in Patients with Sepsis: A Prospective Observational Cohort Study.

Authors:  Ashham Mansur; Benjamin Liese; Maximilian Steinau; Michael Ghadimi; Ingo Bergmann; Mladen Tzvetkov; Aron Frederik Popov; Tim Beissbarth; Martin Bauer; José Hinz
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

3.  Primary bacteraemia is associated with a higher mortality risk compared with pulmonary and intra-abdominal infections in patients with sepsis: a prospective observational cohort study.

Authors:  Ashham Mansur; Yvonne Klee; Aron Frederik Popov; Joachim Erlenwein; Michael Ghadimi; Tim Beissbarth; Martin Bauer; José Hinz
Journal:  BMJ Open       Date:  2015-01-06       Impact factor: 2.692

4.  Retrospective study of prognostic factors in pediatric invasive pneumococcal disease.

Authors:  Nan-Chang Chiu; Hsin Chi; Chun-Chih Peng; Hung-Yang Chang; Daniel Tsung-Ning Huang; Lung Chang; Wei-Te Lei; Chien-Yu Lin
Journal:  PeerJ       Date:  2017-01-25       Impact factor: 2.984

5.  Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2.

Authors:  Zhiding Wang; Dejun Sun; Guojiang Chen; Ge Li; Shuaijie Dou; Renxi Wang; He Xiao; Chunmei Hou; Yan Li; Jiannan Feng; Beifen Shen; Gencheng Han
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

6.  Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study.

Authors:  Eizo Watanabe; Osamu Nishida; Yasuyuki Kakihana; Motoi Odani; Tatsuaki Okamura; Tomohiro Harada; Shigeto Oda
Journal:  Shock       Date:  2020-06       Impact factor: 3.533

7.  The CTLA-4 rs231775 GG genotype is associated with favorable 90-day survival in Caucasian patients with sepsis.

Authors:  Caspar Mewes; Benedikt Büttner; José Hinz; Ayelet Alpert; Aron Frederik Popov; Michael Ghadimi; Tim Beissbarth; Mladen Tzvetkov; Shai Shen-Orr; Ingo Bergmann; Ashham Mansur
Journal:  Sci Rep       Date:  2018-10-11       Impact factor: 4.379

Review 8.  Factors Underlying Racial Disparities in Sepsis Management.

Authors:  Matthew DiMeglio; John Dubensky; Samuel Schadt; Rashmika Potdar; Krzysztof Laudanski
Journal:  Healthcare (Basel)       Date:  2018-11-19

9.  Favorable 90-Day Mortality in Obese Caucasian Patients with Septic Shock According to the Sepsis-3 Definition.

Authors:  Caspar Mewes; Carolin Böhnke; Tessa Alexander; Benedikt Büttner; José Hinz; Aron-Frederik Popov; Michael Ghadimi; Tim Beißbarth; Dirk Raddatz; Konrad Meissner; Michael Quintel; Ingo Bergmann; Ashham Mansur
Journal:  J Clin Med       Date:  2019-12-24       Impact factor: 4.241

10.  Sepsis and Critical Illness Research Center investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients.

Authors:  Tyler J Loftus; Juan C Mira; Tezcan Ozrazgat-Baslanti; Gabriella L Ghita; Zhongkai Wang; Julie A Stortz; Babette A Brumback; Azra Bihorac; Mark S Segal; Stephen D Anton; Christiaan Leeuwenburgh; Alicia M Mohr; Philip A Efron; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge
Journal:  BMJ Open       Date:  2017-08-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.